Marizyme (MRZM) Issued Coverage off FDA Feedback for Pediatric Stroke Treatment


(NEW YORK)– Marizyme, Inc. (OTC: MRZM), a biotechnology company focused on its clinically-tested and patented use of protease therapeutic platform called Krillase™.

FDA Feedback Regarding Pediatric Stroke

The Company recently announced that they have received FDA feedback regarding their development plan for Krillase™ (MB102) in pediatric stroke. In preparation for initiating development activities for MB102, Marizyme requested feedback from the FDA using a Pre-IND application for a Type B meeting request.

MB102 is a novel and patent pending formulation of endovascularly delivered proteases that have demonstrated the capability to quickly and safely remove clots causing ischemic blockages in human vasculature. The first indication will be ischemic stroke in pediatrics as there are currently no approved thrombolytic therapies approved for use in children suffering from ischemic stroke.

Here is a breakdown of Marizyme current pipeline products:

MB101 – Therapy for Complex Infected Wounds & Burns: Completed Phase 1 trials
MB102 – Therapy for Acute Ischemic Stroke: Nearing end of pre-clinical stage
MB103 – Therapy for Ischemic Myocardial Infarcs: Halfway through pre-clinical stage
MB104 – Therapy for Deep Vein Thrombosis: Early pre-clinical stage

Research Coverage Initiated

Ludlow Research, a small cap equity research firm based in New York City, announced it had initiated research coverage on Marizyme (MRZM) based on their unique treatment for ischemic stroke, and high retail demand for biotechnology investments.

To get a feel of the potential MRZM holds one can look at Hancock Jaffe Laboratories (NASDAQ: HJLI), which develops bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI stock recently caught investors interest spiking from $1.40 to nearly $3.50 on positive earnings, and closure of funding for the company.

Portola Pharmaceuticals (NASDAQ: PTLA) is another player in this field that’s focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases.

Register for Research Report Update

To receive an updated copy of Ludlow Research’s report on MRZM register online at

About Marizyme, Inc.

Marizyme, Inc. is a development-stage company dedicated to the commercialization of therapies that address the urgent need of higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on developing treatments for disease caused by thrombus (stroke, acute myocardial infarctions or AMIs and deep vein thrombosis or DVTs), and chronic wound care conditions. These conditions combine for over $26 billion dollars in potential market opportunity and are responsible for sending over millions of patients to the hospital every year in the U.S. alone.

The Company’s first product candidates are derived from Krillase™ Technology, a broad intellectual property portfolio around a novel system of proteolytic enzymes. Marizyme completed the acquisition of these assets and intends to develop several product candidates that will address unmet medical needs in the acute care setting. For more information about the Company, visit

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was not compensated for this alert at the time of its release. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. As of date of this alert, WSNC, or any of its affiliates, held no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial adviser before any and all investments.

Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.